前蛋白转化酶枯草溶菌素9抑制剂与血小板功能

Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors and Platelet Function

前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂能显著地降低血浆低密度脂蛋白胆固醇水平,是高脂血症治疗和高危心血管疾病患者二级预防有潜力的手段。越来越多的证据表明,PCSK9抑制剂降低心血管事件的作用可能部分归因于其对血小板功能的影响。PCSK9抑制剂既可通过抑制PCSK9直接降低血小板功能,也可通过调节脂质水平间接降低血小板功能。PCSK9抑制剂对血小板高反应性的改善以及在缺血性心血管疾病急性期的保护作用是值得研究的方向。

Proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors are novel therapeutic strategies significantly lowering plasma level of low density lipoprotein cholesterol,with great potential for the treatment of hyperlipidaemia and secondary prevention of cardiovascular disease patients at high-risk.Accumulating evidence shows that PCSK9 inhibitors reduce cardiovascular events partially due to their inhibitory effect on platelet function.PCSK9 inhibitors may directly attenuate platelet function through inhibiting PCSK9,or indirectly affect platelet function through influencing lipid levels.The efficacy of PCSK9 inhibitors on improving platelet hyperreactivity and the potential benefit of administering PCSK9 inhibitors at acute phase of ischaemic cardiovascular disease are worthy of further study.